NF-κB Inhibition Restores Sensitivity to Fas-Mediated Apoptosis in Lymphoma Cell Lines
- 1 December 2003
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1010 (1) , 232-236
- https://doi.org/10.1196/annals.1299.041
Abstract
Failure to perform the Fas-related apoptosis pathway can account for tumor resistance both to chemotherapeutic agents and to immunological effectors. We studied the role of NK-kappaB in Fas-resistance, employing the Fas-sensitive human T-lymphoma HuT78 cell line and its Fas-resistant variants HuT78B1 and HuT78G9. All these cell lines expressed high levels of constitutively activated NF-kappaB. Pretreatment of cells with NF-kappaB inhibitors (PDTC, MG132, or SN50) strongly enhanced CH11-induced apoptosis in HuT78 and Hut78G9 cells, while only MG132 showed a similar potentiating effect in HuT78B1. The described synergism was significantly inhibited by pretreatment with the anti-Fas-blocking antibody ZB4 or with the pancapsase inhibitor Z-VAD-FMK, but not by capsase-8 or -9 inhibitors. Overall, these data suggest that NF-kappaB inhibition may restore the Fas-pathway in Fas-resistant NF-kappaB-overexpressing tumors.Keywords
This publication has 4 references indexed in Scilit:
- The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosisCell Death & Differentiation, 1998
- Constitutive Activation of NF-κB Causes Resistance to Apoptosis in Human Cutaneous T Cell Lymphoma HuT-78 CellsPublished by Elsevier ,1998
- DNA Damaging Agents Induce Expression of Fas Ligand and Subsequent Apoptosis in T Lymphocytes via the Activation of NF-κB and AP-1Molecular Cell, 1998
- Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cellsNature Medicine, 1996